KAYLA GLOVER: Open Payments
NPI 1376001420 · HAMMOND, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,366 in 74 payments from 23 companies in 2025. Trend: 2023 $971 · 2024 $557 · 2025 $1,366
Food & beverage: $1,366
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $169 |
| GlaxoSmithKline, LLC. | 7 | $136 |
| Lilly USA, LLC | 8 | $124 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $104 |
| ABBVIE INC. | 5 | $94 |
| Novo Nordisk Inc | 5 | $90 |
| Amgen Inc. | 5 | $81 |
| Esperion Therapeutics, Inc. | 4 | $75 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
Products named: MOUNJARO, CAPLYTA, FARXIGA, BREZTRI, TRELEGY ELLIPTA, NEXLETOL, QULIPTA, REXULTI.
Industry payments across LA — which companies pay providers there.
